Clinical ProgressAptose has made progress in progressing tuspetinib in the clinic, including initiating and reporting early safety and efficacy data from TUSCANY, a Phase 1/2 triplet combo study in newly diagnosed acute myeloid leukemia.

Financial StabilityThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

Treatment EfficacyTwo FLT3-WT patients achieved complete remissions by the end of Cycle 1, with a patient having biallelic TP53 mutations and a complex karyotype achieving a complete remission.

Bears Say

Funding NeedsAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.

Aptose Biosciences News

Aptose Biosciences Appoints Ernst & Young as New Auditor

The latest announcement is out from Aptose Biosciences ( ($TSE:APS) ). Aptose Biosciences has selected Ernst & Young...

1d ago

Aptose Biosciences Secures $2M Advance for AML Therapy

The latest announcement is out from Aptose Biosciences ( ($TSE:APS) ). On July 15, 2025, Aptose Biosciences announced...

18d ago

Aptose Biosciences Upgrades to OTCQB Market Listing

An update from Aptose Biosciences ( ($TSE:APS) ) is now available. Aptose Biosciences announced its upgrade to trade...

1M ago

Aptose Biosciences Defers Loan Interest Payments to Enhance Financial Flexibility

Aptose Biosciences ( ($TSE:APS) ) has provided an announcement. Aptose Biosciences announced an agreement with Hanmi Pharmaceutical to...

1M ago

Aptose Biosciences Secures $8.5M Loan Agreement

Aptose Biosciences ( ($TSE:APS) ) has shared an announcement. On June 20, 2025, Aptose Biosciences Inc. announced a...

1M ago

Aptose Biosciences Secures $8.5M Loan for AML Therapy

Aptose Biosciences ( ($TSE:APS) ) just unveiled an update. On June 20, 2025, Aptose Biosciences announced a new...

1M ago

Aptose Biosciences Secures Cash Advance Amid Financial Uncertainty

Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. Aptose Biosciences has secured a short-term cash advance from...

2M ago

Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML

Aptose Biosciences ( ($TSE:APS) ) has issued an update. Aptose Biosciences has announced promising data from its TUSCANY...

2M ago

Aptose Biosciences Approves Key Resolutions at Shareholder Meeting

Aptose Biosciences ( ($TSE:APS) ) has provided an update. On May 27, 2025, Aptose Biosciences held its Annual...

2M ago

Aptose Biosciences Begins 120 mg Dosing in TUSCANY Trial

Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. On May 20, 2025, Aptose Biosciences announced the dosing...

2M ago

APTOF FAQ

What was Aptose Biosciences Inc.’s price range in the past 12 months?

Aptose Biosciences Inc. lowest stock price was $0.64 and its highest was $17.10 in the past 12 months.

What is Aptose Biosciences Inc.’s market cap?

Aptose Biosciences Inc.’s market cap is $3.11M.

When is Aptose Biosciences Inc.’s upcoming earnings report date?

Aptose Biosciences Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 5 days.

How were Aptose Biosciences Inc.’s earnings last quarter?

Aptose Biosciences Inc. released its earnings results on May 08, 2025. The company reported -$2.61 earnings per share for the quarter, beating the consensus estimate of -$2.67 by $0.06.

Is Aptose Biosciences Inc. overvalued?

According to Wall Street analysts Aptose Biosciences Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aptose Biosciences Inc. pay dividends?

Aptose Biosciences Inc. does not currently pay dividends.

What is Aptose Biosciences Inc.’s EPS estimate?

Aptose Biosciences Inc.’s EPS estimate is -2.74.

How many shares outstanding does Aptose Biosciences Inc. have?

Aptose Biosciences Inc. has 2,552,429 shares outstanding.

What happened to Aptose Biosciences Inc.’s price movement after its last earnings report?

Aptose Biosciences Inc. reported an EPS of -$2.61 in its last earnings report, beating expectations of -$2.67. Following the earnings report the stock price went up 6.452%.

Which hedge fund is a major shareholder of Aptose Biosciences Inc.?

Currently, no hedge funds are holding shares in APTOF

Company Description

Aptose Biosciences Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.